Document rr5nNZexD4dQE8wEvyXZj28a

MEMORANDUM OF MEETING August 11, 1972 : Between : FDA Representatives : Robert M. Schaffner, Ph.D. Director, Off. Prod. Tech. BF-400 Benjamin M. Gutterman, Asst. Dir. for Coord, OPT., BF-402 Alfred Weissler, Ph.D., Actg. Director, DCCT, BF-430 John M. Gowdy, M . D . , Asst. Dir. for Med. A f f ., DCCT, BF-432 John A. Wenninger, Actg. Chief, Cosmetics Branch, DCCT BF-433 Howard N. Pippin, Chief, Guidelines & Compliance Res., BF-312 and James H. Merritt, President, CTFA John Warley, Counsel for CTFA W. W a s h e d .Ph.D. , Johnson & Johnson : ..... R. Rolle, Johnson & Johnson Dvid H.;:Hamer, Johnson & Johnson A. J. Goudie, Ph.D., Johnson & Johnson Ian Stewart, Ph.D., McCrone Assoc. - Johnson & Johnson Robert Giovacchini, Ph.D., Gillette Med. Eval. Lab. Frederick Roesch, Whittaker, Clark .& Daniels, Inc. G.A. Sprott, Avon Products Harold Schwartz, Ph.D., The Mennen Company Murray Berdick, P h . D . , Chesebrough-Pond`s Inc. Seymour.; Z. Lewin, New York University Subject: Asbestos d.n Cosmetics Containing Talc, Such as Dusting; .Powders and Face Powders. The meeting was held at''FDA, 200 "C" Street, S.W. , Washington, D.C. , Dr.. Schaffner indicated that the meeting was requested by .several individual companies as well as the Cosmetic Toiletry and Fragrance Association. The purpose of the meeting was to discuss preliminary results of the analysis of over 100 talc containing cosmetic pro ducts for asbestos contamination. The results indicated that over 40% of the samples may contain asbestiform minerals such as chrysotile or tremolite. The. analyses were carried out by Dr. Lewin of New York University, under contract to FDA. Dr. Schaffner reported that FDA was preparing a "Proposed Statement of Policy" on "Asbestos in Cosmetics Containing Talc, Such As Dusting Powders and Pace. Powders." Dr. Schaffner indicated that when Dr. Le w i n 1s final report i s :accepted by FDA it will be put on file with p ::: r Page 2 . The Hearing Clerk at the time the "Proposed Statement of Policy" is published in the Federal Register. Mr. Merritt strongly objected to the possibility that FDA would make the analytical results public in such-a way as to give brand names '^ E and manufacturers. Mr. Merritt indicated that such a disclosure of randomly selected samples in the market place would result In a great economic hardship for the companies involved-and their employees. Dr. Schaffner said that he was advised that the final report would ffr: have to be released to the public., Mr. Merritt said that i n his opinion that ^ c ^ L s not legally the ease and attempts by FDA to make the report public may cause CTFA to bake legal action to prevent EiE public disclosure. Mr. Merritt said the report, if released, should not disclose product and company names. Mr. Merritt continued by stating the FDA has/traditionally operated with as great a reliance on voluntary industry, compliance as possible. Dr. Schaffner indicated that public disclosure of such a report was official FDA p;:;;;; H 'policy. - Mr . Merritt indicated that such po l i c y had not been es.tab- = lished since the"final order on "Freedom of Information" has not yet been published in the Federal Register. liiE iii Dr. Berdick, serving as scientific spokesman for the industry group, asked if they could have D r . Lewin outline the analytical methodology used to analyze for asbestos in talc containing cosmetic products. D r . Lewin reported that he used X-ray diffraction as a means of detecting chrysotile and tremolite (two-species of asbestos) in the-talc samples7 analyzed. The other mineral species he detected in the samples7would not./interfere with the analysis. The method has an apparent -behsitivity of approximately .1 or 2%. The principal source b f ambiguity by X-ray diffraction was rthe overlap of chrysotile and chlorite peaks ;in the diffraction pattern. No problems were . noted with detection of tremolite. Chrysotile and chlorite could be differentiated b y an independent analytical technique known as "differential thermal-analysis" (DTA). Dr. Lewin then proceeded to review for the group the graphs obtained from analyses of talc by X-ray diffraction and DTA. - The industry group indicated that tremolite can occur in a non-fibrous form and therefore may not present a safety hazard. Dr. Lewin reported that optical microscopy could be used to differentiate massive form from fiber from for a particular species. It was agreed by all present that the -massive form of tremolite should, not be considered as asbestos. A discussion of the merits of the use of electron micrographs for the detection of asbestos in talc products took place at this point in the meeting. Fage 3. Dr. Berdick asked if all the cosmetic samples analyzed by Dr. Lewin were analyzed by more than one m ethod, namely, x-ray diffraction. Dr. Lewin indicated only a few of the x-ray diffrac tion results were confirmed by other methods. Dr. Nashed of Johnson and Johnson (J&J) reported work they had done on a J&J product which Dr. Lewin reported as having chrysotile. Dr. Nashed reported that J&J scientists (Dr. Stewart and Mr. Rolle supervised the analyses) had examined a portion of the very same sample that Dr. Lewin had analyzed and .found no detectable chrysotile. They reportedly used the following techniques, petrographic analysis, electron microscopy, electron diffraction, powder camera x-ray, scanning x-ray and step scanning x-ray. J&J scientists were confident that had their sample contained chrysotile they would have found it. From the code on the sample analyzed by Dr. Lewin they were able to isolate one sample from reserved stocks for each month that the product was manufactured from February 1970 to August 1971. Each sample was analyzed for chrysotile and no detectable amount was found. A technical discussion on the. reliability of the various analytical methods used to detect chrysolite was carried out at this point in the meeting. Dr. Berdick suggested that Dr. L ewin's results should be verified before any public disclosure of the results is contemplated by FDA. He suggested that Dr. Lewin report as it stands is incomplete. Dr. Berdick echoed Mr. Merritt's earlier statement that publication of the results (which he felt needed confirmation) at the present time would do great harm to any company. If the results should be in error there is virtually no way to undo the harm. Dr. Nashed said that J&J would make all analytical data on the analyses of their talc sample available to FDA on a non-confidential basis in the very near future. Dr. Schaffner asked Dr. Lewin how long it would take to confirm his findings. Dr. Lewin thought that if the confirmation were carried out by optical microscopy it would take about four weeks. Dr. Schaffner indicated that a final report on these samples (about 40) would be expected before October 1, 1972. There was no disagreement between FDA and industry scientists present at this meeting about the potential safety hazard that the presence of asbestos in talc containing cosmetic product poses to the consumer. cc : BF-1 (Dr. Wodicka); BF-400(Dr. Schaffner); BF-433 BF-300 (Dr. Angelotti) ; BF-430 (D.r. Weissler) (BF-433) JAWenninger)